Updates in Immunotherapy for Pancreatic Cancer DOI Open Access
Robert C. Chick, Timothy M. Pawlik

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(21), С. 6419 - 6419

Опубликована: Окт. 26, 2024

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options. Due to a variety of cancer cell-intrinsic factors, including KRAS mutations, chemokine production, and other mechanisms that elicit dysregulated host immune response, PDAC often characterized by poor infiltration immune-privileged fibrotic stroma. As understanding the tumor microenvironment (TME) evolves, novel therapies are being developed target immunosuppressive mechanisms. Immune checkpoint inhibitors have efficacy when used alone or radiation. Combinations therapies, along chemotherapy chemoradiation, demonstrated promise in preclinical early clinical trials. Despite dismal response rates for immunotherapy metastatic PDAC, neoadjuvant somewhat encouraging, suggesting incorporation treatment should be earlier disease course. Precision therapy may informed advances transcriptomic sequencing can identify immunophenotypes, allowing more appropriate selection each individual patient. Personalized antigen-specific increasing topic interest, adjuvant using personalized mRNA vaccines prevent recurrence. Further development will need balance precision generalizability cost.

Язык: Английский

Neuroscience in peripheral cancers: tumors hijacking nerves and neuroimmune crosstalk DOI Creative Commons

Hua‐yang Fan,

Xin‐hua Liang, Ya‐ling Tang

и другие.

MedComm, Год журнала: 2024, Номер 5(11)

Опубликована: Окт. 31, 2024

Abstract Cancer neuroscience is an emerging field that investigates the intricate relationship between nervous system and cancer, gaining increasing recognition for its importance. The central governs development of directly affects brain tumors, peripheral (PNS) shapes tumor microenvironment (TME) tumors. Both systems are crucial in cancer initiation progression, with recent studies revealing a more role PNS within TME. Tumors not only invade nerves but also persuade them through remodeling to further promote malignancy, creating bidirectional interaction cancers. Notably, immune cells contribute this communication, forming triangular influences protumor inflammation effectiveness immunotherapy. This review delves into mechanisms connecting focusing on how various cell types influence nerve‒tumor interactions, emphasizing clinical relevance nerve‒immune dynamics. By deepening our understanding interplay nerves, cells, has potential reshape biology insights, inspire innovative therapies, improve outcomes patients.

Язык: Английский

Процитировано

6
Exploring the biological mechanism and clinical value of perineural invasion in pancreatic cancer DOI
Hao Yuan, Yufeng Zhang, Fengyuan Liu

и другие.

Cancer Letters, Год журнала: 2025, Номер unknown, С. 217515 - 217515

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Injectable anticancer biodegradable hydrogel-based nanocomposites: Synergistic pH-responsive paclitaxel/β-cyclodextrin nanocomplex delivery in polyvinyl alcohol hydrogel for targeted pancreatic ductal adenocarcinoma treatment DOI
Xiuxiu Li, Wenjing Ma, Xu Zhou

и другие.

International Journal of Pharmaceutics, Год журнала: 2025, Номер unknown, С. 125514 - 125514

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Updates in Immunotherapy for Pancreatic Cancer DOI Open Access
Robert C. Chick, Timothy M. Pawlik

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(21), С. 6419 - 6419

Опубликована: Окт. 26, 2024

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options. Due to a variety of cancer cell-intrinsic factors, including KRAS mutations, chemokine production, and other mechanisms that elicit dysregulated host immune response, PDAC often characterized by poor infiltration immune-privileged fibrotic stroma. As understanding the tumor microenvironment (TME) evolves, novel therapies are being developed target immunosuppressive mechanisms. Immune checkpoint inhibitors have efficacy when used alone or radiation. Combinations therapies, along chemotherapy chemoradiation, demonstrated promise in preclinical early clinical trials. Despite dismal response rates for immunotherapy metastatic PDAC, neoadjuvant somewhat encouraging, suggesting incorporation treatment should be earlier disease course. Precision therapy may informed advances transcriptomic sequencing can identify immunophenotypes, allowing more appropriate selection each individual patient. Personalized antigen-specific increasing topic interest, adjuvant using personalized mRNA vaccines prevent recurrence. Further development will need balance precision generalizability cost.

Язык: Английский

Процитировано

1